- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.04. | DIAGONAL BIO AB: Diagonal Bio announces change of news plattform | 1 | Cision News | ||
| 04.03. | Diagonal Bio AB: Diagonal Bio has been approved for delisting from Nasdaq First North Growth Market | 267 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that Nasdaq has approved Diagonal Bio's application for delisting from Nasdaq First North Growth Market ("First North"). The... ► Artikel lesen | |
| 04.03. | Diagonal Bio AB: Diagonal Bio has received conditional approval for listing on NGM Nordic SME | 220 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has received conditional approval for listing on NGM Nordic SME ("NGM"). The first day of trading is planned for 19 March 2025. This means that... ► Artikel lesen | |
| 07.02. | Diagonal Bio AB: Diagonal Bio AB's rights issue of units oversubscribed | 378 | GlobeNewswire (Europe) | The subscription period in Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units of initially approximately SEK 6.0 million ended on 6 February 2025 (the "Rights Issue"). The Rights... ► Artikel lesen | |
| 29.01. | Diagonal Bio AB: Diagonal Bio announces positive pilot test results and secures order from StallZet | 143 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowned horse trainer at StallZet. The order comes as a result of... ► Artikel lesen | |
| DIAGONAL BIO Aktie jetzt für 0€ handeln | |||||
| 22.01. | Diagonal Bio AB: Diagonal Bio AB publishes investment memorandum prior to upcoming rights issue of units | 234 | GlobeNewswire (Europe) | The subscription period of Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units, which was resolved on 23 December 2024 by the Board of Directors together with the resolution on... ► Artikel lesen | |
| 17.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 17.01.2025 | 851 | Xetra Newsboard | Das Instrument 2DV0 FR001400SVN0 DRONE VOLT SACA EO 1 EQUITY wird ex Kapitalmassnahme gehandelt am 17.01.2025 The instrument 2DV0 FR001400SVN0 DRONE VOLT SACA EO 1 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 11.11.24 | Nasdaq Stockholm AB: Diagonal Bio AB receives observation status | 291 | GlobeNewswire | Today, on November 11, 2024, Diagonal Bio AB (the "Company") disclosed a press
release with information on the Company's financial situation.
The rules of Nasdaq First North Growth Market state that... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 16,895 | -0,56 % | Figma, Beam, Intellia: Cathie Wood setzt auf riskante (Bio-)Tech-Aktien | Die bekannte US-Investorin Cathie Wood blieb ihrer Linie auch im August 2025 treu und griff wieder einmal beherzt bei spekulativen Tech- und Biotech-Werten zu. Mit ihrem wichtigsten Fonds, dem ARK Innovation... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,294 | +2,91 % | PacBio Enters Carrier Screening Market With PureTarget Expansion | ||
| CENTOGENE | 0,093 | -0,11 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 4,440 | +2,45 % | Atai Life Sciences files to sell 45.32M common shares by selling shareholders | ||
| BIOMERIEUX | 116,20 | -0,17 % | Dividendenbekanntmachungen (09.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALLSTATE CORPORATION US0200021014 1 USD 0,8776 EUR ALPHABET INC CL A US02079K3059 0,21 USD 0,1842 EUR ALPHABET INC CL C US02079K1079 0... ► Artikel lesen | |
| BIO GREEN MED SOLUTION | 3,813 | -6,40 % | Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd. | KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (Nasdaq: BGMS, Nasdaq: BGMSP) ("Bio Green Med" or the "Company"), a company engaged in diversified industries... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals | ||
| GENUS | 28,600 | +2,14 % | Genus - Total Voting Rights | ||
| ANAPTYSBIO | 26,800 | +1,52 % | AnaptysBio, Inc.: Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026 | Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,950 | +1,60 % | XTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive Officer | Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL") announced... ► Artikel lesen | |
| ABIONYX PHARMA | 3,480 | +1,46 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma: (Paris:ABNX)
Market:... ► Artikel lesen | |
| AKESO | 15,000 | -1,96 % | AKESO (09926): 2025 INTERIM REPORT | ||
| MEIRAGTX | 6,800 | -4,90 % | MeiraGTx Reports Second Quarter 2025 Financial and Operational Results | - Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RIX)... ► Artikel lesen | |
| MAAT PHARMA | 4,290 | +4,38 % | MaaT Pharma Publishes Its Half Year 2025 Results and Provides a Business Update | Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,055 | -14,40 % | Isofol Medical AB: Isofol's clinical study with arfolitixorin reaches another important milestone | GOTHENBURG, Sweden, September 30, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully completed the second dose level in the dose escalating... ► Artikel lesen |
DIAGONAL BIO AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,000 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGONAL BIO AB finden Sie auf Wallstreet Online.